Pfizer is closing in on a potential $7.3bn takeover of anti-obesity drug developer Metsera, which would mark the US pharmaceutical company’s first big deal in two years, in a push to give the drugmaker a foothold in the lucrative weight-loss drug market.
輝瑞(Pfizer)正接近以約73億美元收購抗肥胖藥物開發商Metsera，成為這家大型制藥集團為在利潤豐厚的抗肥胖藥物市場站穩腳跟而達成的最大一筆交易。
您已閱讀10%（331字），剩余90%（3153字）包含更多重要信息，訂閱以繼續探索完整內容，并享受更多專屬服務。